Pfizer’s key oncology drugs are Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi, as well as antibody-drug conjugates or ADCs ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Find out whether you should get the RSV vaccine, known as Abrysvo, during pregnancy and when it's recommended.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.